Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial

The Lancet Oncology
Michael FriedlanderBo Gao

Abstract

Rationale exists for combined treatment with immune checkpoint inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors in a variety of solid tumours. This study aimed to investigate the safety and antitumour effects of pamiparib, an oral PARP 1/2 inhibitor, combined with tislelizumab, a humanised anti-PD-1 monoclonal antibody, in patients with advanced solid tumours and to determine the optimum doses for further evaluation. We did a multicentre, open-label, phase 1a/b study at five academic sites or community oncology centres in Australia. We recruited adults (aged ≥18 years) with advanced solid tumours who had received one or more previous lines of therapy, with an Eastern Cooperative Oncology Group performance score of 1 or less, and a life expectancy of 12 weeks or more. Patients were enrolled into one of five dose-escalation cohorts, with dose-escalation done in a 3 + 3 design. Cohorts 1-3 received intravenous tislelizumab 2 mg/kg every 3 weeks plus 20, 40, or 60 mg oral pamiparib twice daily, respectively; cohorts 4 and 5 received 200 mg intravenous tislelizumab every 3 weeks plus 40 or 60 mg oral pamiparib twice daily, respectively. The primary endpoints of the phase 1a dose-escalation part of the study were safety ...Continue Reading

References

Aug 18, 2006·Seminars in Cancer Biology·Stephan Gasser, David Raulet
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group
Oct 7, 2008·Oncogene·N Nausch, A Cerwenka
Jan 29, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Gordon John Sampson RustinUNKNOWN Gynecological Cancer Intergroup
Apr 29, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey S WeberMary L Disis
Jun 7, 2015·Biochemical and Biophysical Research Communications·Jing HuangMichael S Goldberg
Feb 11, 2016·International Journal of Molecular Sciences·Paul H Hayashi
Jul 9, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roman M ChabanonSophie Postel-Vinay
Oct 13, 2016·Drug Design, Development and Therapy·Xi ZhangJinghua Li
Feb 9, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shiping JiaoMien-Chie Hung
Apr 24, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kent W Mouw, Alan D D'Andrea
Apr 25, 2018·Cancer Immunology, Immunotherapy : CII·Tong ZhangKang Li
Jul 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J B A G HaanenUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

❮ Previous
Next ❯

Citations

Jan 25, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eileen M O'ReillyDavid P Kelsen
Jun 13, 2020·Cancers·Florent Peyraud, Antoine Italiano
Mar 19, 2020·Drugs·Arnold Lee, Susan J Keam
Jun 13, 2020·Frontiers in Pharmacology·Jian-Ye ZhangLi-Wu Fu
Sep 5, 2020·Nature Reviews. Drug Discovery·Nicola J Curtin, Csaba Szabo
Oct 6, 2020·Frontiers in Cell and Developmental Biology·Maddison RoseEmma Bolderson
May 28, 2020·Frontiers in Oncology·Praveen VikasRohan Garje
Jul 31, 2020·Signal Transduction and Targeted Therapy·Qiao WangXia Zhao
Jun 25, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Johann S BergholzJean J Zhao
Oct 27, 2020·Frontiers in Molecular Biosciences·Sangeeta KakotiAtsushi Shibata
Nov 7, 2020·Drug Discovery Today·Samridhi Lal, Timothy J Snape
Jun 26, 2021·Journal of Experimental & Clinical Cancer Research : CR·Yali WangYanmei Zou
Jul 1, 2021·Immunotherapy·Nikolaos CharalampakisDimitrios Schizas
Jul 15, 2021·Cancer Treatment Reviews·Francesco PassigliaGiorgio Vittorio Scagliotti
Jul 22, 2021·Drugs·Anthony Markham
Jul 22, 2021·Nature Reviews. Clinical Oncology·Mariana Paes DiasJos Jonkers
Aug 6, 2019·The Lancet Oncology·Ulrik Lassen
Aug 12, 2021·Nature Reviews. Cancer·Roman M ChabanonSophie Postel-Vinay
Aug 28, 2021·Biomolecules·Mary-Ann XavierBart Cornelissen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.